Gilde Healthcare raises €416 million ($450 million) venture and growth capital fund - Gilde Healthcare

Gilde Healthcare raises €416 million ($450 million) venture and growth capital fund

March 31, 2020

Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Gilde Healthcare today announces the first and final close of Gilde Healthcare V, a €416 million ($450 million) venture and growth capital fund. The new fund, which was oversubscribed, targets growth opportunities in a broad range of healthcare sectors including digital health, medtech and therapeutics both in Europe and North America. The fund will have a special attention for private healthcare companies enabling improved care at affordable cost.

Gilde Healthcare V was raised in a single close and is backed by a balanced mix of international investors including banks, pension funds, fund-of-funds, sovereign funds, endowments, family offices, entrepreneurs and Gilde partners. Disclosed investors include longstanding corporate partner Royal Philips and Rabo Corporate Investments from The Netherlands, HANIEL and KfW Capital from Germany, BNP Paribas Fortis Private Equity and Belgian Growth Fund from Belgium, Danish Growth Fund from Denmark and the European Investment Fund (EIF) from Luxembourg.

Pieter van der Meer, Managing Partner of Gilde Healthcare, said:

“The healthcare landscape in Europe and the US is changing rapidly, driven by the need for more patient centric care and more focus on value based care. With our new fund we will continue our strategy to invest in venture and growth stage companies developing novel solutions that enable better healthcare outcomes at reduced costs. An example is remote monitoring and home care of patients which is now more relevant than ever in the fight against COVID-19.”

Recent Gilde Healthcare exits include the sale of infectious disease (including COVID-19) diagnostic platform STAT-Dx to Qiagen, the trade sale of Breath Therapeutics (treatment of lung transplant rejection) to Zambon Pharma and the NASDAQ listing of Axonics, focused on the treatment of overactive bladder. Gilde Healthcare also has a strong track record with healthcare unicorns such as Ablynx, Ascendis Pharma and uniQure.

Gilde Healthcare’s team is a mix of investment managers, sector experts and serial entrepreneurs. The trans-Atlantic team provides hands-on support to its companies on their international growth paths. The Gilde Healthcare V fund will typically make equity investments in a single portfolio company of between €10-40 million.

 

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, medtech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

For more information, visit the company’s website at www.gildehealthcare.com.

Media Contact

Gilde Healthcare

Pieter van der Meer
Managing Partner
+31 (0)30 219 2565

CFF Communications

Suzanne Bakker
+31 (0)6 1136 8659
suzanne.bakker@cffcommunications.nl

Eline Weltevreede
+31 (0)6 1136 8648
eline.weltevreede@cffcommunications.nl

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024